[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534559":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":35,"responsibleParty":49,"collaborators":25,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":25,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":25,"enrollmentInfo":62,"targetDuration":25,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":25,"overallStatus":72,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"University of Leeds","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Two capsules of placebo taken orally per day for three months",[13],"Drug: Digoxin 0.125 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"Digoxin","EXPERIMENTAL","Two capsules containing 62.5mcg digoxin taken orally per day for three months",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Digoxin 0.125 MG","One capsule containing digoxin per day for three months",[15,9],null,[27,32],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Klaus Witte","CONTACT","00447768254073","k.k.witte@leeds.ac.uk",{"name":33,"role":29,"phone":30,"phoneExt":25,"email":34},"Mark Kearney","m.t.kearney@leeds.ac.uk",[36],{"facility":37,"status":25,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":25},"Leeds Teaching Hospitals NHS Trust","Leeds","West Yorkshire","LS16 5AR","United Kingdom","UK",{"type":44,"coordinates":45},"Point",[46,47],-1.54785,53.79648,{"lat":47,"lon":46},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Klaus K Witte, MD","Senior Lecturer in Cardiology","100534559","phase-2-digoxin-and-senolysis-in-heart-failure-and-diabetes-mellitus-100534559",false,"NCT06240403","Digoxin and Senolysis in Heart Failure and Diabetes Mellitus","Digoxin: a New Senolytic to Repair Dysfunctional Adipose Tissue in Patients With Heart Failure and Type II Diabetes Mellitus","Inclusion Criteria:\n\n* Aged ≥18yrs,\n* HFrEF (LVEF\\\u003C40%)\n* T2DM (taking anti-diabetic medication, fasting plasma glucose ≥7.0 mmol\u002FL and\u002For a serum HbA1c \\>48mmol\u002FL\n* On optimal medical therapy,\n* Able\u002Fprepared to give informed written consent.\n\nExclusion Criteria:\n\n* Significant cognitive impairment,\n* Important co-morbidity limiting ability to comply with study procedures,\n* Hyperkalemia (\\>5.5mmol\u002FL)\n* eGFR\\\u003C30ml\u002Fmin\u002F1.73m2\n* Current\u002Fprevious (\\\u003C6m) participation in other studies.","ALL","18 Years",{"count":63,"type":64},100,"ESTIMATED","INTERVENTIONAL",[67],"PHASE2","In pilot studies the investigators have shown that subcutaneous adipose tissue (SAT) from patients with reduced ejection fraction heart failure (HFrEF) and type 2 diabetes mellitus (T2DM) is dysfunctional. Endothelial cells from the adipose tissue from these patients are senescent and have deleterious effects on healthy human subcutaneous adipocytes, including increasing expression of IL-6 (gene and protein) and reducing glucose uptake. Digoxin, a well-established treatment for HFrEF, selectively clears these senescent endothelial cells and prevents adipocyte dysfunction. This study will examine the effect of digoxin on adipose tissue on the burden of senescent cells.",[70,71],"Heart Failure, Systolic","Diabetes Mellitus, Type 2","NOT_YET_RECRUITING","2024-12-04",{"date":75,"type":76},"2024-12-06","ACTUAL",{"date":78,"type":64},"2025-09-01",{"date":80,"type":64},"2029-08-28",{"name":5,"class":6},1]